title: Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center.
abstract: We describe the natural history of lupus nephritis (LN) in a historical cohort of 190 white patients with the diagnosis of biopsy-proven LN followed in a single reference center.We evaluated 670 patients with systemic lupus erythematosus (SLE) consecutively followed in our department from 1970 until 2006. All patients fulfilled the 1997 revised criteria for the classification of SLE. White patients (Spanish-born) with biopsy-proven LN were selected as the study population.The cohort included 190 patients (170 female patients and 20 male) with a mean age at LN diagnosis of 31 years. Renal biopsy revealed type I LN in 8 (4%) patients, type II in 33 (17%), type III in 46 (24%), type IV in 72 (38%), type V in 28 (15%), and type VI in 3 (2%) patients. Induction remission was achieved in 85% of patients with types I and II, 78% with type III, 70% with type IV, and 32% of patients with type V. After a mean follow-up of 2391 patient-years, 62 (33%) patients developed chronic renal failure and 18 (9%) evolved to end-stage renal disease. Adjusted multivariate Cox regression analysis identified male sex (hazard ratio [HR], 4.33) and elevated creatinine at LN diagnosis (HR, 5.18) as independent variables for renal failure. Survival was 92% at 10 years of follow-up, 80% after 20 years, and 72% after 30 years.Our results suggest that biopsy-proven LN in white patients has an excellent prognosis. Ethnicity should be considered a key factor when evaluating the prognosis and therapeutic response to different agents in patients with LN.
authors.affiliation: From Laboratory of Autoimmune Diseases "Josep Font," Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Autoimmune Diseases (AS, MRC, AB, PBZ, NS, NN, AT, MPL, CDL, AD), and Hypertension Unit, Department of Internal Medicine (AC), Institut Clínic de Medicina i Dermatologia, Hospital Clínic, Barcelona; Nephrology Service (AD), Hospital Clínic, Department of Medicine, University of Barcelona, Barcelona; Statistical Unit, Department of Public Health, School of Medicine, University of Barcelona (JS), Barcelona; and Centre de Salut Les Corts, Primary Care Research Group (IDIBAPS), Department of Medicine, University of Barcelona, GesClinic (AS), Barcelona, Spain.
authors.forename: Antoni
authors.initials: A
authors.lastname: Sisó
authors.forename: Manuel
authors.initials: M
authors.lastname: Ramos-Casals
authors.forename: Albert
authors.initials: A
authors.lastname: Bové
authors.forename: Pilar
authors.initials: P
authors.lastname: Brito-Zerón
authors.forename: Natalia
authors.initials: N
authors.lastname: Soria
authors.forename: Norma
authors.initials: N
authors.lastname: Nardi
authors.forename: Adriana
authors.initials: A
authors.lastname: Testi
authors.forename: Marta
authors.initials: M
authors.lastname: Perez-de-Lis
authors.forename: Cándido
authors.initials: C
authors.lastname: Díaz-Lagares
authors.forename: Alejandro
authors.initials: A
authors.lastname: Darnell
authors.forename: Juan
authors.initials: J
authors.lastname: Sentís
authors.forename: Antonio
authors.initials: A
authors.lastname: Coca
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D001424:Bacterial Infections / Q000453:epidemiology; D001706:Biopsy; D015897:Comorbidity; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007668:Kidney / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D008017:Life Expectancy; D008181:Lupus Nephritis / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology*; D008297:Male; D016896:Treatment Outcome; D014777:Virus Diseases / Q000453:epidemiology; D044465:White People / Q000706:statistics & numerical data*
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents
references.citation: Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol. 1995;22:1265-1270.
references.citation: Adler M, Chambers S, Edwards C, Neild G, Isenberg D. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford). 2006;45:1144-1147.
references.citation: Alamanos Y, Voulgari PV, Papassava M, Tsamandouraki K, Drosos AA. Survival and mortality rates of systemic lupus erythematosus patients in northwest Greece. Study of a 21-year incidence cohort. Rheumatology (Oxford). 2003;42:1122-1123.
references.citation: Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, Vila LM, Reveille JD; LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168-1172.
references.citation: Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med. 1987;83:877-885.
references.citation: Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001-2010.
references.citation: Barber CE, Geldenhuys L, Hanly JG. Sustained remission of lupus nephritis. Lupus. 2006;15:94-101.
references.citation: Barr RG, Selinger S, Appel GB, Zuniga R, D'Agati V, Salmon J, Radhakrishnan J. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 2003;18:2039-2046.
references.citation: Bastian HM, Alarcon GS, Roseman JM, McGwin G Jr, Vila LM, Fessler BJ, Reveille JD; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. Rheumatology (Oxford). 2007;46:683-689.
references.citation: Beji S, Kaaroud H, Ben Moussa F, Abderrahim E, Goucha R, Ben Hamida F, Hedri H, El Younsi F, Ben Abdallah T, Kheder A, Ben Maiz H. Nephropathie lupique: a propos de 211 cas. Rev Med Interne. 2005;26:8-12.
references.citation: Bertsias GK, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, Isenberg D, Kallenberg CG, Khamashta M, Piette JC, Schneider M, Smolen J, Sturfelt G, Tincani A, van Vollenhoven R, Boumpas DT, Gordon C. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints. Ann Rheum Dis. 2009;68:477-483.
references.citation: Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM. 1999;92:211-218.
references.citation: Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AR, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340:741-745.
references.citation: Burling F, Ng J, Thein H, Ly J, Marshall MR, Gow P. Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: results from a multi-ethnic New Zealand cohort. Lupus. 2007;16:830-837.
references.citation: Cameron JS, Turner DR, Ogg C, Williams DG, Lessof MH, Chantler C, Leibowitz S. Systemic lupus erythematosus with nephritis: a long-term study. Q J Med. 1979;48:1-24.
references.citation: Cervera R, Font J, Shoenfeld Y. European Working Party on Systemic Lupus Erythematosus. European Working Party on Systemic Lupus Erythematosus: a 15-year report. Autoimmun Rev. 2006;5:549-553.
references.citation: Chan TM, Tse KC, Tang CS, Mok MY, Li FK; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076-1084.
references.citation: Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, Nahar N, de La Cuesta C, Hurtado A, Fornoni A, Beltran-Garcia L, Asif A, Young L, Diego J, Zachariah M, Smith-Norwood B. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int. 2006;69:1846-1851.
references.citation: Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971-980.
references.citation: Coplon NS, Diskin CJ, Petersen J, Swenson RS. The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med. 1983;308:186-190.
references.citation: Cortes-Hernandez J, Ordi-Ros J, Labrador M, Segarra A, Tovar JL, Balada E, Vilardell M. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus. 2003;12:287-296.
references.citation: Courtney PA, Fogarty DG. Lupus nephritis in Northern Ireland: implications for nephritis screening. Rheumatology (Oxford). 2002;41(Suppl 2):106.
references.citation: El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus. 2003;12:692-696.
references.citation: Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006;33:1563-1569.
references.citation: Font J, Cervera R, Ramos-Casals M, Garcia-Carrasco M, Sents J, Herrero C, del Olmo JA, Darnell A, Ingelmo M. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum. 2004;33:217-230.
references.citation: Font J, Ramos-Casals M, Cervera R, Garcia-Carrasco M, Torras A, Siso A, Darnell A, Ingelmo M. Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM. 2001;94:19-26.
references.citation: Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219-2228.
references.citation: Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, Derksen RH, Berden JH; Dutch Working Party on Systemic Lupus Erythematosus. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006;70:732-742.
references.citation: Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
references.citation: Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido E, Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R. Immunosuppresive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121-2131.
references.citation: Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from the long-term follow-up of the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50:3934-3940.
references.citation: Huong DL, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, Godeau P, Piette JC. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine (Baltimore). 1999;78:148-166.
references.citation: Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, Steinberg AD, Gourley MF, Klippel JH, Balow JE, Boumpas DT. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46:995-1002.
references.citation: Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15:366-370.
references.citation: Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000;35:904-914.
references.citation: Korbet SM, Schwartz MM, Evans J, Lewis EJ; Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18:244-254.
references.citation: Levey AS, Lan SP, Corwin HL, Kasinath BS, Lachin J, Neilson EG, Hunsicker LG, Lewis EJ. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study: results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med. 1992;116:114-123.
references.citation: Li C, Gordon C, Skan J, Isenberg DA. An analysis of end stage renal failure in SLE patients in the UK: experience of a combined cohort in London and Birmingham. Rheumatology (Oxford). 2002;41(Suppl 2):107.
references.citation: Liang L, Yang X, Xu H, Zhan Z, Ye Y, Yu X, Chen W. Clinical predictors of recovery and complications in the management of recent-onset renal failure in lupus nephritis: a Chinese experience. J Rheumatol. 2004;31:701-706.
references.citation: McLaughlin JR, Bombardier C, Farewell VT, Gladman DD, Urowitz MB. Kidney biopsy in systemic lupus erythematosus. Arthritis Rheum. 1994;37:559-567.
references.citation: Mosca M, Bencivelli W, Neri R, Pasquariello A, Batini V Puccini R, Tavoni A, Bombardieri S. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 2002;61:1502-1509.
references.citation: Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001;59:2156-2163.
references.citation: Neumann K, Wallace DJ, Azen C, Nessim S, Fichman M, Metzger AL, Klinenberg JR. Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum. 1995;25:47-55.
references.citation: Petri M. The effect of race on incidence and clinical course in systemic lupus erythematosus: The Hopkins Lupus Cohort. J Am Med Womens Assoc. 1998;53:9-12.
references.citation: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med. 1991;324:150-154.
references.citation: Rivera TL, Belmont HM, Malani S, Latorre M, Benton L, Weisstuch J, Barisoni L, Tseng CE, Izmirly PM, Buyon JP, Askanase AD. Current therapies for lupus nephritis in an ethnically heterogeneous cohort. J Rheumatol. 2009;36:298-305.
references.citation: Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, Erdozain JG, Aguirre C. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577-583.
references.citation: Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20-28.
references.citation: Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria N, Munoz S, Testi A, Plaza J, Sentis J, Coca A. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus. 2008;17:281-288.
references.citation: Varela DC, Quintana G, Somers EC, Rojas-Villarraga A, Espinosa G, Hincapie ME, McCune WJ, Cervera R, Anaya JM. Delayed lupus nephritis. Ann Rheum Dis. 2008;67:1044-1046.
references.citation: Wallace DJ, Podell TE, Weiner JM, Cox MB, Klinenberg JR, Forouzesh S, Dubois EL. Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med. 1982;72:209-220.
references.citation: Ward MM. Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis. Kidney Int. 2000;57:2136-2143.
references.citation: Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241-250.
references.citation: Williams W, Shah D, Sargeant LA. The clinical and epidemiologic features in 140 patients with lupus nephritis in a predominantly black population from one center in Kingston, Jamaica. Am J Med Sci. 2004;327:324-329.
references.citation: Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, Rozman B, Isenberg DA, Sturfelt G, Nived O, Turney JH, Venalis A, Adu D, Smolen JS, Emery P. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis. 2004;63:525-529.